Investor directory

Adicet Bio

Adicet Bio is a biotechnology company focused on the design and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing its lead product candidate, ADI-001, which is a first-in-class therapy that targets CD20 and is aimed at treating autoimmune diseases as well as relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. In addition to ADI-001, Adicet Bio is also developing ADI-270, an armored gamma delta CAR T cell candidate that targets renal cell carcinoma, with potential applications for other solid tumors and hematological malignancies. The company is currently in the pre-clinical stage of its research and development efforts.

Top Stages

Acquisition
http://www.adicetbio.com
https://crunchbase.com/organization/adicet-bio
https://linkedin.com/company/adicet-bio-inc
https://pitchbook.com/profiles/company/122840-38
https://twitter.com/adicetbio
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=310073311

Nick Harvey

CFO

1 past transactions

Applied Immune Technologies

Acquisition in 2016
Applied Immune Technologies Ltd. is involved in the development of therapeutic molecules aimed at treating cancer, viral infections, and autoimmune diseases. The company specializes in creating T-Cell Receptor-Like (TCRL) antibodies that target intracellular-derived peptides for various therapeutic and diagnostic purposes. These TCRL antibodies have applications in pathology, as well as in vaccine design, validation, and monitoring. Additionally, they are useful in analyzing antigen presentation in various diseases. Founded in 2006 and based in Haifa, Israel, the company was previously known as BioMimic Pharma and now operates as a subsidiary of Adicet Bio, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.